Boston Scientific Corporation $BSX Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 0.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,786,959 shares of the medical equipment provider’s stock after selling 64,744 shares during the quarter. Ameriprise Financial Inc. owned about 0.53% of Boston Scientific worth $838,114,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of BSX. 1248 Management LLC acquired a new stake in shares of Boston Scientific during the first quarter valued at $26,000. FWL Investment Management LLC purchased a new position in Boston Scientific in the 2nd quarter valued at about $26,000. Sound Income Strategies LLC lifted its holdings in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. Kilter Group LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter worth about $30,000. Finally, Princeton Global Asset Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $32,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent analyst reports. Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Wells Fargo & Company increased their price target on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. The Goldman Sachs Group restated a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, October 22nd. Finally, Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $124.43.

Boston Scientific Stock Up 0.9%

BSX opened at $92.58 on Friday. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The firm has a 50 day moving average price of $98.85 and a 200 day moving average price of $101.64. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The company has a market cap of $137.24 billion, a PE ratio of 49.51, a price-to-earnings-growth ratio of 1.85 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the previous year, the firm earned $0.63 earnings per share. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 143,095 shares of company stock valued at $14,228,950. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.